Novo Nordisk CEO says experimental weight loss pill could become a best-in-class drug

[ad_1]
Novo Nordisk CEO on latest trials, U.S. obesity and demand outlook

Novo Nordisk CEO Lars Fruergaard Jørgensen on Friday said the company's experimental weight loss pill, amycretin, could eventually become a best-in-class treatment for obesity. 

The Danish drugmaker is racing to capitalize on the runaway success of its blockbuster weight loss drug Wegovy by developing a new generation of treatments for obesity, including more convenient and potentially cheaper pills. 

His remarks came one day after Novo Nordisk impressed investors with early-stage trial data on amycretin. Patients on the pill lost about 13.1% of their weight after 12 weeks, Jørgensen said on CNBC's "Money Movers." 

That surpasses the 6% weight loss seen in those who took Wegovy after the same time period. It also adds to the growing enthusiasm around the potential of weight loss pills. 

Lars Fruergaard Jørgensen, CEO of Novo Nordisk, speaks during an interview in New York on Aug. 10, 2022.

Christopher Goodney | Bloomberg | Getty Images

Along with convenience for patients, pills could help alleviate some of the supply constraints plaguing weight loss injections. Wegovy, along with similar drugs, has soared in demand and slipped into intermittent shortages over the past year due to its ability to help patients shed significant weight over time. 

"We believe in the future there'll be different segments of anti-obesity treatments, with different patients having different preferences," Jørgensen told CNBC. "Some will prefer an injectable and we really believe that once we can take a pill, it's a very convenient offering."

But those pills won't join the market any time soon. A midstage trial on amycretin will begin in the second half of this year, with results expected in early 2026, the company said Thursday. 

In a separate interview with Reuters on Friday, Novo Nordisk's head of development Martin Holst Lange said the company is comfortable in being able to launch amycretin this decade.

Amycretin suppresses appetite by targeting the same gut hormone that Wegovy mimics, which is known as GLP-1. But amycretin also targets a pancreas hormone called amylin, which affects hunger.

U.S.-traded shares of Novo Nordisk rose as much as 8.3% on Thursday after the company released the data, extending the past year's 68% gain. But the company's stock fell 2% on Friday. 

Don’t miss these stories from CNBC PRO:

[ad_2] Source link https://worldnews2023.com/health/novo-nordisk-ceo-says-experimental-weight-loss-pill-could-become-a-best-in-class-drug/?feed_id=294206&_unique_id=660435fcc7f73

Comments

Post a Comment

Popular posts from this blog

Real Housewives of Beverly Hills couple Kyle Richards and Mauricio Umansky ‘seperate’

Image
[ad_1] Stay ahead of the trend in fashion and beyond with our free weekly Lifestyle Edit newsletter Stay ahead of the trend in fashion and beyond with our free weekly Lifestyle Edit newsletter Real Housewives of Beverly Hills ’ Kyle Richards and Mauricio Umansky have reportedly separated after 27 years of marriage. Richards joined the popular Bravo reality series in 2010 with Umansky making regular appearances over the last 13 years. “Kyle and Mauricio have been separated for a while now but are still living under the same roof. They remain amicable as they figure out what’s next for them and their family,” a source confirmed to People on Monday (3 July). The separation will affect both Real Housewives , which is gearing up for its 13th season, and the Netflix reality series Buying Beverly Hills, which follows Umansky’s real estate business as two of their daughters work as agents. Richards has already filmed the second season of the Netflix show, according to Deadline . The I
Read more

Pfizer RSV vaccine for infants has 'generally favorable' safety data, FDA staff say

Image
[ad_1] Blood sample for respiratory syncytial virus (RSV) test Jarun011 | Istock | Getty Images U.S. Food and Drug Administration staff on Tuesday said Pfizer's vaccine that protects infants from respiratory syncytial virus has "generally favorable" safety data. The FDA staff made the conclusion in briefing documents ahead of a meeting on Thursday when a panel of external advisors to the agency will discuss whether to recommend full approval of the RSV shot . The advisors will vote on whether Pfizer's late-stage clinical trial data on the vaccine supports its safety and efficacy. The FDA typically follows the advice of its advisory committees, but is not required to do so. The agency is slated to make a decision on whether to clear the shot in August before RSV season in the fall. If approved, Pfizer's jab would become the world's first vaccine that protects infants against RSV.  RSV usually causes mild, cold-like symptoms. But infants and older ad
Read more

Casemiro has improved Man Utd: Maguire | The Express Tribune

Image
[ad_1] LONDON: Casemiro scored twice as Manchester United turned on the style to beat 10-man Reading 3-1 and reach the FA Cup fifth round on Saturday as Tottenham forward Son Heung-min ended his recent goal drought. On a day lacking major shocks, there were wins for Premier League strugglers Leeds, Leicester and Southampton but Fulham were held by Championship side Sunderland. United – fourth in the Premier League and within touching distance of a place in the League Cup final – produced more compelling evidence they are back on track under new manager Erik ten Hag . The home side took the lead at Old Trafford in the 54th minute when Anthony produced a defence-splitting pass to find Brazil teammate Casemiro, who lifted the ball over goalkeeper Joe Lumley. Four minutes later United were two up, when Casemiro let fly with a stunning strike from outside the box to find the bottom corner. With the home side brimming with confidence, substitute Fred produced an audacious flic
Read more